# Texas to Conduct Its Own Ibogaine Clinical Trials – Clinical Insights > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/texas-ibogaine-clinical-trials-psychedelic-research/ > **Published:** 2026-04-01T16:04:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:44-04:00 > **Clinical Summary:** Explore Texas ibogaine clinical trials advancing state-level psychedelic research with focus on addiction treatment and cardiac safety protocols. --- ✦ New CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic [Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)Psychedelics[State Policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/)Cardiac SafetyResearch Why This Matters Texas joining state-level psychedelic research represents a significant shift in regulatory approach, potentially accelerating clinical access pathways outside traditional federal frameworks. This could create important precedents for how states navigate controlled substance research when federal progress stalls. Clinical Summary Texas has announced plans to conduct independent [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) of ibogaine, a psychedelic alkaloid derived from the iboga plant traditionally used in [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). Ibogaine has shown preliminary promise for opioid use disorder and other substance dependencies, though it carries significant cardiac risks including QT prolongation and arrhythmias. The compound remains Schedule I federally, making state-level research programs particularly noteworthy as alternative regulatory pathways. Dr. Caplan’s Take “We’re seeing states step into the research vacuum created by federal scheduling constraints. While promising for access, clinicians need robust safety protocols given ibogaine’s cardiac toxicity profile — this isn’t a compound for casual investigation.” Clinical Perspective 🧠 Clinicians should monitor emerging state-level research programs as potential future treatment options while maintaining awareness of ibogaine’s serious cardiovascular contraindications. Any future clinical use will require careful patient screening, cardiac monitoring, and specialized protocols given the compound’s unique risk profile compared to other psychedelics. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Texas%20to%20conduct%20its%20own%20ibogaine%20clinical%20trials%20-%20The%20Texas%20Tribune%20%40drcaplan&url=https%3A//www.texastribune.org/2026/03/31/texas-ibogaine-research-clinical-trials-psychedelics/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.texastribune.org/2026/03/31/texas-ibogaine-research-clinical-trials-psychedelics/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Texas%20to%20conduct%20its%20own%20ibogaine%20clinical%20trials%20-%20The%20Texas%20Tribune%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.texastribune.org/2026/03/31/texas-ibogaine-research-clinical-trials-psychedelics/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.texastribune.org/2026/03/31/texas-ibogaine-research-clinical-trials-psychedelics/](https://www.texastribune.org/2026/03/31/texas-ibogaine-research-clinical-trials-psychedelics/) Table of Contents - [FAQ](#FAQ)[What clinical areas does this news relate to?](#What_clinical_areas_does_this_news_relate_to) - [What is the clinical relevance rating for this information?](#What_is_the_clinical_relevance_rating_for_this_information) - [Why is cardiac safety mentioned in relation to cannabis and psychedelics?](#Why_is_cardiac_safety_mentioned_in_relation_to_cannabis_and_psychedelics) - [How does state policy impact clinical practice with these substances?](#How_does_state_policy_impact_clinical_practice_with_these_substances) - [What should addiction medicine specialists know about this update?](#What_should_addiction_medicine_specialists_know_about_this_update) - [Related](#Related) ## FAQ #### What clinical areas does this news relate to? This news covers [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/), psychedelics, [state policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/), and cardiac safety. It appears to focus on cannabis-related clinical developments with high relevance for healthcare providers. #### What is the clinical relevance rating for this information? This news has been assigned a “High Clinical Relevance” rating (#80). This indicates strong evidence or policy relevance with direct implications for clinical practice. #### Why is cardiac safety mentioned in relation to cannabis and psychedelics? Cannabis and psychedelic substances can have cardiovascular effects that clinicians need to monitor. Understanding these cardiac safety considerations is crucial for safe patient management and screening. #### How does state policy impact clinical practice with these substances? State policy changes regarding cannabis and psychedelics directly affect what treatments clinicians can legally prescribe or recommend. Healthcare providers must stay informed about evolving regulations in their jurisdictions. #### What should addiction medicine specialists know about this update? This high-relevance update likely contains important information about treatment protocols, safety considerations, or policy changes affecting [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). Specialists should review this information to ensure current best practices in patient care. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Texas to conduct its own ibogaine [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) – The Texas Tribune”, “url”: “https://www.texastribune.org/2026/03/31/texas-ibogaine-research-clinical-trials-psychedelics/”, “datePublished”: “2026-04-01T16:28:58Z”, “about”: “texas conduct its own ibogaine clinical”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Texas will launch its own clinical trials into ibogaine psychedelic after failing to find a drug …](https://cedclinic.com/state-sponsored-psychedelic-research-texas-ibogaine-trials/) Detailed coverage of Texas's plans to initiate independent ibogaine clinical trials following federal research limitations. [Read More](https://cedclinic.com/state-sponsored-psychedelic-research-texas-ibogaine-trials/) [Trump Plans To Sign Executive Order On The Psychedelic Ibogaine As Soon As This Week …](https://cedclinic.com/ibogaine-opioid-use-disorder-treatment-executive-order/) Insights into federal policy shifts regarding ibogaine and potential impacts on [clinical research](https://cedclinic.com/endocannabinoid-system-stroke-prevention/) and access. [Explore Policy Update](https://cedclinic.com/ibogaine-opioid-use-disorder-treatment-executive-order/) [Trump set to ease restrictions on psychedelic drug used to treat PTSD | Reuters](https://cedclinic.com/psychedelic-drug-policy-developments-ptsd-treatment/) Analysis of federal regulatory easing on psychedelics, including implications for treatment of PTSD and addiction. [Learn More](https://cedclinic.com/psychedelic-drug-policy-developments-ptsd-treatment/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).